SCHEMBL423688

SCHEMBL423688

O=CNS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.57
CA2 P00918 3/20 0.57
CA12 O43570 2/20 0.57
CA3 P07451 2/20 0.57
CA4 P22748 2/20 0.57
CA6 P23280 2/20 0.57
CA5A P35218 2/20 0.57
CA7 P43166 2/20 0.57
CA9 Q16790 2/20 0.57
CA13 Q8N1Q1 2/20 0.57
CA14 Q9ULX7 2/20 0.57
CA5B Q9Y2D0 2/20 0.57
MMP1 P03956 1/20 0.57
MMP2 P08253 1/20 0.57
MMP9 P14780 1/20 0.57
MMP8 P22894 1/20 0.57
MMP13 P45452 1/20 0.57
CES1 P23141 1/20 0.55
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL92828 0.79 CA1 (0.56) CA1CA2CA12CA3CA4
SCHEMBL9135659 0.78 CA2 (0.57) CA1CA2CA12CA9CA14
SCHEMBL17764 0.78 GAA (0.59) CA1CA2CA12CA9MMP1
SCHEMBL423265 0.78 CA1 (0.57) CA1CA2MMP1MMP2MMP9
SCHEMBL11751509 0.78 CA1 (0.57) CA1CA2CA12CA4CA6
SCHEMBL6926687 0.77 CA2 (0.67) CA1CA2CA12CA3CA4
SCHEMBL426189 0.76 PGR (0.62)
SCHEMBL14540208 0.75 TDP1 (0.53) CA1CA2MMP1MMP2MMP9
SCHEMBL12353348 0.75 CA2 (0.64) CA1CA2CA12CA3CA4
SCHEMBL7527514 0.74 MEN1 (0.58) CA1CA2CA12CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014186623-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE BIOMED VALLEY DISCOVERIES (US) 2014-11-20 WO claimed
US-20030216571-A1 Antiallergens; antiinflammatory agents UBE INDUSTRIES, LTD. (JP) 2003-11-20 US claimed
EP-1254897-A1 TRICYCLIC COMPOUNDS Ube Industries, Ltd. (JP) 2002-11-06 EP claimed
EP-0528633-B1 Pyrimidinyl acetamides as elastase inhibitors ZENECA LTD (GB) 2000-10-18 EP claimed
EP-0636142-B1 LACTAM PEPTIDES HAVING HLE INHIBITING ACTIVITY ZENECA LTD (GB) 1998-06-17 EP claimed
EP-0636143-B1 ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS ZENECA LTD (GB) 1997-09-24 EP claimed
EP-0636141-B1 PYRIMIDINYL ACETAMIDES AS ELASTASE INHIBITORS ZENECA LTD (GB) 1997-06-25 EP claimed
EP-0630382-B1 LACTAM DIPEPTIDES HAVING HLE INHIBITING ACTIVITY ZENECA LTD (GB) 1997-02-26 EP claimed
EP-0585155-B1 Trifluoromethylketone derivatives of peptides having HLE inhibiting activity, their preparation and pharmaceutical composition ADIR (FR) 1996-12-11 EP claimed
US-5565429-A HUMAN LEUCOCYTE ELASTASE INHIBITORS; EMPHYSEMA; ANTIARTHRITIC AGENTS; RHEUMATIC DISEASES ADIR ET COMPAGNIE (FR) 1996-10-15 US claimed
EP-0630382-A1 LACTAM DIPEPTIDES HAVING HLE INHIBITING ACTIVITY. ZENECA LTD (GB) 1994-12-28 EP claimed
EP-0585155-A1 Trifluoromethylketone derivatives of peptides having HLE inhibiting activity, their preparation and pharmaceutical composition ADIR ET COMPAGNIE (FR) 1994-03-02 EP claimed
WO-1993021212-A1 LACTAM DIPEPTIDES HAVING HLE INHIBITING ACTIVITY ZENECA LIMITED (GB) 1993-10-28 WO claimed
WO-1993021214-A1 ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS ZENECA LIMITED (GB) 1993-10-28 WO claimed
WO-1993021210-A1 PYRIMIDINYL ACETAMIDES AS ELASTASE INHIBITORS ZENECA LIMITED (GB) 1993-10-28 WO claimed
WO-1993021213-A1 ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS ZENECA LIMITED (GB) 1993-10-28 WO claimed
WO-1993021209-A1 LACTAM PEPTIDES HAVING HLE INHIBITING ACTIVITY ZENECA LIMITED (GB) 1993-10-28 WO claimed
US-5254558-A Substituted 1,3-diazines as leukocyte elastase inhibitors IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-10-19 US claimed
EP-0528633-A1 Pyrimidinyl acetamides as elastase inhibitors ZENECA LIMITED (GB) 1993-02-24 EP claimed
EP-0249349-B1 DIFLUOROKETO COMPOUNDS ICI AMERICAS INC. (US) 1992-10-14 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216571-A1 Antiallergens; antiinflammatory agents CYSLTR2, CYSLTR1, LTC4S CA1 2057/4885CA2 307/4885CA12 2965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.